论文部分内容阅读
以逆转录病毒ｐＬＸＳＮ与人ＩＬ２ｃＤＮＡ基因进行重组，包装ＰＡ３１７细胞，建立逆转录病毒包装体系细胞ＰＡ３１７／ｐＬＩＬ２ＳＮ。用病毒上清液转导人淋巴细胞（ＴＩＬ，ＰＢＬ）和３株人腺癌细胞株（ＳＰＣＡ１，ＭＫＮ４５，ＨｅｐＧ２）对转ＩＬ２基因的淋巴细胞（ＴＩＬ／ＩＬ２，ＰＢＬ／ＩＬ２）和转ＩＬ２基因的人癌细胞（ＳＰＣＡ２／ＩＬ２，ＭＫＮ４５／ＩＬ２，ＨｅｐＧ２／ＩＬ２）进行体外安全性实验，即ｅｎｖ基因检测（ＰＣＲ方法），辅助病毒检测（ＮＩＨ３Ｔ３放大实验），支原体污染检查（ＰＣＲ方法），热原反应（动物实验）。以上实验证明，以ｐＬＸＳＮ逆转录病毒介导外源基因的抗肿瘤基因治疗是安全、可行的
Recombinant retrovirus pLXSN and human IL-2 cDNA gene were recombined, and PA317 cells were packaged to establish retroviral packaging system cells PA317/pLIL-2SN. Transfection of human peripheral lymphocytes (TIL, PBL) and three human adenocarcinoma cell lines (SPC-A1, MKN-45, HepG2) to lymphocytes (IL/2, transgene IL-2) using viral supernatants PBL/IL-2 and human IL-2 gene cancer cells (SPCA2/IL2, MKN45/IL2, HepG2/IL2) were subjected to in vitro safety test, ie env gene detection (PCR method) ), Helper virus detection (NIH3T3 amplification experiment), Mycoplasma contamination test (PCR method), Pyrogen reaction (animal experiment). The above experiments prove that it is safe and feasible to use pLXSN retrovirus to mediate the anti-tumor gene therapy of foreign genes.